Friday, September 02, 2022
Sense Biodetection, a global innovator in molecular diagnostics, has announced a strategic partnership with TECOmedical for the distribution of Sense's Veros COVID-19 test. Veros COVID-19 is the first test on the rapid, instrument-free Veros molecular testing platform, designed for point-of-care use.
The Veros COVID-19 test is a self-contained, single-use product that provides PCR-quality results in approximately 15 minutes, without the need for a reader or external power source. TECOmedical, a leading specialty medical distributor and a Eurobio Scientific Company, has a proven track record in developing new markets with innovative technologies. The agreement between Sense and TECOmedical initially covers distribution in Germany and Austria, with pending regulatory approval for Switzerland. This partnership is part of Sense's planned distribution strategy in the European Union as it brings the Veros platform to market.
Ryan Roberts, Chief Commercial Officer of Sense, expressed his excitement about partnering with TECOmedical to introduce Veros COVID-19, highlighting TECOmedical's excellent reputation among its customers. He believes that by adding the instrument-free Veros COVID-19 test to their diagnostic portfolio, TECOmedical's customers will have access to a laboratory-quality molecular test that enables improved access and faster diagnosis, ultimately enhancing patient care at the point of use.
Marieluise Wippermann, CEO of TECOmedical, emphasized their commitment to bringing innovative technologies that address unmet needs. Offering an instrument-free, PCR-quality test result within minutes at the point of care aligns with their goal of overcoming limitations of existing technologies and improving patient care. TECOmedical is eager to launch Veros COVID-19 and looks forward to an expanded Veros test menu in the future.
Veros is a groundbreaking molecular diagnostic testing platform that is rapid, single-use, and instrument-free, delivering lab-quality results in approximately 15 minutes. Using proprietary rapid molecular amplification technology, Veros aims to improve access to rapid and highly accurate point-of-care testing, contributing to the fight against COVID-19 by enabling faster and more precise diagnoses.
The clinical performance of Veros COVID-19 was established through a comprehensive clinical trial conducted during the Delta and Omicron variant surges of the pandemic. The study included nearly 300 evaluable subjects across multiple centers, all in near-patient testing or point-of-care environments. The test operators had no prior laboratory training or experience, yet 100% of them agreed that Veros COVID-19 was easy to use, read, and understand the results, requiring minimal hands-on time.
Veros COVID-19 has demonstrated 100% conservation in detecting all Variants of Interest and Concern identified by the WHO and the US CDC, including various sub-variants of the Omicron variant, ensuring its effectiveness in the face of evolving virus strains.
